Cancer research has significantly improved patient outcomes, but the translation of funding into therapeutic advancements has been limited. This article discusses strategies to promote innovation and discoveries in cancer research. Despite heavy funding, many studies are redundant, irreproducible, and unnecessary. Traditional treatments like surgery, chemotherapy, and radiotherapy remain key, but newer therapies face challenges such as limited availability, high costs, and resistance. Holistic approaches, which consider cancer as a complex system, are gaining traction, offering insights into tumor heterogeneity and microenvironment. However, these approaches have limitations in identifying key factors and generalizability. The article highlights the need for a balance between reductionism and holism, prioritizing proteomics over transcriptomics, and fostering data transparency. It also suggests transforming the peer review process and rethinking research funding to prioritize impactful discoveries. The example of the rapid development of COVID-19 vaccines shows the potential for centralized, focused efforts in cancer research. The article calls for innovative strategies, including supercollaborations and prioritizing translational research, to achieve significant therapeutic breakthroughs and improve cancer survival and quality of life.Cancer research has significantly improved patient outcomes, but the translation of funding into therapeutic advancements has been limited. This article discusses strategies to promote innovation and discoveries in cancer research. Despite heavy funding, many studies are redundant, irreproducible, and unnecessary. Traditional treatments like surgery, chemotherapy, and radiotherapy remain key, but newer therapies face challenges such as limited availability, high costs, and resistance. Holistic approaches, which consider cancer as a complex system, are gaining traction, offering insights into tumor heterogeneity and microenvironment. However, these approaches have limitations in identifying key factors and generalizability. The article highlights the need for a balance between reductionism and holism, prioritizing proteomics over transcriptomics, and fostering data transparency. It also suggests transforming the peer review process and rethinking research funding to prioritize impactful discoveries. The example of the rapid development of COVID-19 vaccines shows the potential for centralized, focused efforts in cancer research. The article calls for innovative strategies, including supercollaborations and prioritizing translational research, to achieve significant therapeutic breakthroughs and improve cancer survival and quality of life.